Needham Maintains Buy on Viridian Therapeutics, Lowers Price Target to $40
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Serge Belanger has maintained a 'Buy' rating on Viridian Therapeutics (NASDAQ:VRDN), but lowered the price target from $47 to $40.
August 10, 2023 | 8:39 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Needham analyst has maintained a 'Buy' rating on Viridian Therapeutics but lowered the price target from $47 to $40.
The news is directly related to Viridian Therapeutics. While the 'Buy' rating is maintained, the lowering of the price target might indicate a slower growth expectation, which could potentially impact the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100